SCHEMBL11901700

SCHEMBL11901700

C[C@H](NC(=O)OC(C)(C)C)C(=O)Nc1ccccc1Nc1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.48
AAK1 Q2M2I8 5/20 0.46
RAF1 P04049 1/20 0.44
KDR P35968 1/20 0.44
MAP2K2 P36507 1/20 0.44
MAP2K1 Q02750 1/20 0.44
AURKB Q96GD4 1/20 0.44
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
HDAC4 P56524 3/20 0.40
HDAC1 Q13547 2/20 0.40
JAK2 O60674 2/20 0.40
MEF2D Q14814 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11901156 0.87 CTSS (0.43) CTSBCTSSCTSKHDAC4HDAC1
SCHEMBL1752668 0.87 EGFR (0.53) EGFRAAK1RAF1KDRMAP2K2
SCHEMBL12682883 0.87 DDX3X (0.44) EGFRAAK1HDAC4HDAC1JAK2
SCHEMBL11900838 0.84 NR1H4 (0.42) CTSBCTSSCTSKHDAC1RXFP1
SCHEMBL11901699 0.81 CTSS (0.43) EGFRAAK1CTSSCTSKHDAC4
SCHEMBL11901223 0.80 CTSS (0.42) EGFRAAK1CTSSCTSKHDAC4
SCHEMBL12473109 0.80 CTSS (0.42) EGFRAAK1CTSSCTSKHDAC4
SCHEMBL11901858 0.78 CTSS (0.41) AAK1CTSSCTSKHDAC4HDAC1
SCHEMBL11902012 0.78 CTSS (0.41) AAK1CTSSCTSKHDAC4HDAC1
SCHEMBL11900816 0.78 CTSS (0.41) AAK1CTSSCTSKHDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 EGFR 2123/4885AAK1 1089/4885RAF1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.